Treatment of Neuromyelitis Optica With Rituximab Retrospective Analysis of 25 Patients
Treatment of Neuromyelitis Optica With Rituximab Retrospective Analysis of 25 Patients
复制标题
DOI：
10.1001/archneur.65.11.noc80069
复制
发表时间：
2008-11-01
影响因子：
--
通讯作者：
Cree, Bruce A. C.
中科院分区：
文献类型：
--
作者：
Jacob, Anu;Weinshenker, Brian G.;Cree, Bruce A. C.
背景：视神经脊髓炎（NMO）是一种罕见的、危及生命的炎症性脱髓鞘疾病。最近，人们对其免疫发病机制有了很多了解。然而，尚未确定具有预期结果的最佳治疗方法。目的：评估利妥昔单抗治疗 NMO 的使用和疗效。设计：使用利妥昔单抗治疗 NMO 患者的回顾性多中心病例系列。地点：美国和英国的 7 个三级医疗中心。患者：25 名患者（包括 2 名儿童），其中 23 名患者尽管使用其他药物但仍出现复发。 利妥昔单抗之前的药物。包括对 7 名先前报告的患者进行延长随访。干预措施：以 8 个月的中位间隔输注利妥昔单抗。主要结果指标：年化复发率和残疾（以扩展残疾状态量表评分表示）。结果：在中位随访 19 个月时，中位年化治疗后复发率低于治疗前率（0 [范围 0-3.2] 与 1.7 [范围， 0.5-5]复发，P
Background: Neuromyelitis optica (NMO) is an uncommon, life-threatening inflammatory demyelinating disorder. Recently, much has become known about its immunopathogenesis. However, optimal treatments, with expected outcomes, have not been established.Objective: To evaluate the use and efficacy of rituximab for treating NMO.Design: Retrospective multicenter case series of NMO patients treated with rituximab.Setting: Seven tertiary medical centers in the United States and England.Patients: Twenty-five patients (including 2 children), 23 of whom experienced relapses despite use of other drugs before rituximab. Extended follow-up of 7 previously reported patients is included.Interventions: Infusions of rituximab at median intervals of 8 months.Main Outcome Measures: Annualized relapse rate and disability (expressed as Expanded Disability Status Scale score).Results: At a median follow-up of 19 months, the median annualized posttreatment relapse rate was lower than the pretreatment rate (0 [range 0-3.2] vs 1.7 [range, 0.5-5] relapses, P